focus -WSS

focus

author：focus 2025-09-28 13:23:31 - browse：9

Illustration of a doctor and patient. The shadow behind the doctor displays 0s and 1s for artificial intelligence. –– health tech coverage from STAT — Molly Ferguson for STAT

The world’s largest technology companies are racing to build generative AI into every corner of health and medicine.

Microsoft has formed an alliance with the electronic health records vendor Epic to wire the technology into dozens of health software products. Google is infusing it into tools used by hospitals to collect and organize data on millions of patients. Not to be outdone, Amazon has unveiled a service to help build clinical note scribes, and is separately working to embed generative AI in drug research and development.

All of this has unfolded faster than federal regulators could blink — or answer questions about how the technology should be tested and evaluated, whether it will help or hurt patients, and how it will impact privacy and the use of personal data.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What the airline industry can learn from medicine

WSS

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Childbirth

Mega Millions pot grows to $1.25 billion after no winner

Do more moles mean more problems? Not so, says new study

Scientists inch closer to single

Infectious disease expert Jeanne Marrazzo assumes Fauci role

explore

focus

knowledge

Drug repurposing or repositioning? The language matters

Report: NIH

Virginia high school admissions case could be legal follow

Focused ultrasound for uterine fibroids: an uphill battle

Medicare proposal to cover medical devices draws a mixed reaction

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Guidelines to prevent youth baseball injuries need more muscle

Adults seen as increasingly susceptible to measles

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

iTeos Therapeutics debuts first data on TIGIT

hotspot

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Adults seen as increasingly susceptible to measles

David Sabatini, ex

Biohaven protein

EQRx, failed developer of low

New safety details link Apellis eye drug to rare cases of blindness

hotspot

entertainment

Wikipedia

knowledge